Relation of blast cell survival and proliferation to chemotherapy resistance in AML

British Journal of Haematology

Volumn 93, Issue 4, 1996, Pages 888-897

  Nørgaard, Jan M ^a,b   Langkjer, Sven T ^a   Palshof, Torben ^a   Clausen, Niels ^a   Pedersen, Bent ^a   Hokland, Peter ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b Medicinsk Afdeling C   (Denmark)

Author keywords

AML; cell survival; drug resistance; myeloid growth factors; proliferation

Indexed keywords

ACLARUBICIN; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 3; MICROSOMAL AMINOPEPTIDASE; MITOXANTRONE; TETRAZOLIUM; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BLAST CELL; CELL PROLIFERATION; CELL VIABILITY; CHILD; COLORIMETRY; DRUG RESISTANCE; HUMAN; HUMAN CELL; INFANT; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0029996946     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1996.d01-1735.x     Document Type: Article

References (64)

1. Bell, R., Rohatiner, A.Z.S., Slevin, M.L., Ford, J.M., Dhaliwal, H.S., Henry, G., Birkhead, B.G., Amess, J.A.L., Malpas, J.S. & Lister, T.A. (1982) Short-term treatment for acute myelogenous leukaemia. British Medical Journal, 284, 1221-1224.
2. Bennett, J.M., Catovsky, D., Daniel, M.T., Flandrin, G., Galton, D.A.G., Gralnick, H.R. & Sultan, C. (1976) Proposals for the classification of acute leukaemias. British Journal of Haematology, 33, 451-458.
3. Bennett, J.M., Catovsky, D., Daniel, M.T., Flandrin, G., Galton, D.A.G., Gralnick, H.R. & Sultan C. (1985) Proposed revised criteria for the classification of acute myeloid leukaemia. Annals of Internal Medicine, 103, 620-625.
4. Bennett, J.M., Catovsky, D., Daniel, M.T., Flandrin, G., Galton, D.A.G., Gralnick, H.R. & Sultan, C. (1991) Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-MO). British Journal of Haematology, 78, 325-329.
5. Bodley, A., Liu, L.F., Israel, M., Seshadri, R., Koseki, Y., Giuliani, F.C., Kirschenbaum, S., Silber, R. & Potmesil, M. (1989) DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA. Cancer Research, 49, 5969-5978.
6. Brach, M., Klein, H., Platzer, E., Mertelsmann, R. & Hermann, F. (1990) Effect of interleukin 3 on cytosine arabinoside-mediated cytotoxicity of leukemia myeloblasts. Experimental Hematology, 18, 748-753.
7. Bradbury, D., Zhu, Y-M, & Russell, N. (1994) Regulation of Bcl-2 expression and apoptosis in acute myeloblastic leukemia cells by granulocyte-macrophage colony-stimulating factor. Leukemia, 8, 786-791.
8. Bradstock, K., Matthews, J., Benson, E., Page, F. & Bishop, J. (1994) Prognostic value of immunophenotyping in acute myeloid leukemia. Blood, 84, 1220-1225.
9. Budel, L.M., Touw, I.P., Delwel, R., Clark, S.C. & Löwenberg, B. (1989) Interleukin-3 and granulocyte-monocyte colony-stimulating factor on human acute myelocytic leukemia cells and relationship to proliferative response. Blood, 74, 565-571.
10. Butturini, A., Santucci, M.A., Gale, R.P., Perocco, P. & Tura, S. (1990) GM-CSF incubation prior to treatment with cytarabine or doxorubicin enhances drug activity against AML cells in vitro: a model for leukemia chemotherapy. Leukemia Research, 14, 743-749.
11. Campana, D., Coustan-Smith, E., Manabe, A., Buschle, M., Raimondi, S.C., Behm, F.G., Ashmun, R., Aricò, M., Biondi, A. & Pui, C-H. (1993) Prolonged survival of B-lineage acute lymphohlastic leukemia cells is accompanied by overexpression of bcl-2 protein. Blood, 81, 1025-1031.
12. Campos, L., Guyotat, D., Archimbaud, E., Calmard-Oriol, P., Tsuruo, T., Troncy, J., Treille, D. & Fiere, D. (1992) Clinical significance of multidrug resistance p-glycoprotein expression on acute non-lymphoblastic leukemia cells at diagnosis. Blood, 79, 473-476.
13. Campos, L., Rouault, J-P., Sabido, O., Oriol, P., Roubi, N., Vasselon, C., Archimbaud, E., Magaud, J-P. & Guyotat, D. (1993) High expression of bcl-2 protein in acute myeloid leukemia is associated with poor response to chemotherapy. Blood, 81, 3091-3096.
14. Campos, L., Sabido, O., Rouault, J-P. & Guyotat, D. (1994) Effects of bcl-2 antisense oligodeoxynucleotides on in vitro proliferation and survival of normal marrow progenitors and leukemic cells. Blood, 84, 595-600.
15. Ellison, R.R., Holland, J.F., Weil, M., Jacquillat, C., Boiron, M., Bernard, J., Sawitsky, A., Rosner, F., Gussof, B., Silver, R.T., Karansas, A., Cuttner, J., Spurr, C.L., Hayes, D.M., Blom, J., Leone, L.A., Haurani, F., Kyle, R., Hutchison, J.L., Jackson Forcier, R. & Moon, J.H. (1968) Arabinosyl cytosine: useful agent in the treatment of acute leukemia in adults. Blood, 32, 507-523.
16. Gajewski, J.L., Ho, W.G., Nimer, S.D., Hirji, K.F., Gekelman, L., Jacobs, A.D. & Champlin, R.E. (1989) Efficacy of intensive chemotherapy for acute myelogenous leukemia associated with a preleukemic syndrome. Journal of Clinical Oncology, 7, 1637-1645.
17. Greaves, M.F. (1993) Stem cell origins of leukaemia and curability. British Journal of Cancer, 67, 413-423.
18. Griffin, J.D., Davis, R., Nelson, D.A., Davey, F.R., Mayer, R.J., Schiffer, C., Ross McIntyre, O. & Bloomfield, C.D. (1986) Use of surface marker analysis to predict outcome of adult acute myeloblastic leukemia. Blood, 68, 1232-1241.
19. Hamblin, T. (1992) The treatment of acute myeloid leukemia preceded by myelodysplastic syndrome. Leukemia Research, 16, 101-108.
20. Hansen, O.P., Pedersen-Bjergaard, J., Ellegaard, J., Brincker, H., Boesen, A.M., Christensen, B.E., Drivsholm, Aa., Hippe, E., Jans, H., Jensen, K.B., Killmann, S-Aa., Jensen, M.K., Karle, H., Laursen, B., Nielsen, J.B., Nissen, N.I. & Thorling, K. (1991) Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. Leukemia, 5, 510-516.
21. Hockenbery, D., Nuñez, G., Milliman, C., Schreiber, R.D. & Korsmeyer, S.J. (1990) Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature, 348, 334-338.
22. Hoyle, C.F., de Bastos, M., Wheatley, K., Sherrington, P.D., Fischer, P.J., Rees, J.K.H., Gray, R. & Hayhoe, F.G.J. (1989) AML associated with previous cytotoxic therapy, MDS or myeloproliferative disorders: results from the MRC's 9th AML trial. British Journal of Haematalogy, 72, 45-53.
23. Huet, O., Petit, J.M., Ratinaud, H. & Julien, R. (1992) NADH-dependent dehydrogenase activity estimation by flow cytometric analysis of 3-(4,5-dimethylthiazolyl-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction. Cytometry, 13, 532-539.
24. Hunter, A.E., Rogers, S.Y., Roberts, I.A.G., Barrett, J. & Russell, N. (1995) Autonomous growth of blast cells is associated with reduced survival in acute myeloblastic leukemia. Blood, 82, 899-903.
25. Jenkins, J.R., Ayton, P., Jones, T., Davies, S.L., Simmons, D.L., Harris, A.L., Sheer, D. & Hickson, I.D. (1992) Isolation of cDNA clones encoding the β isoenzyme of human DNA topoisomerase II and localization of the gene to chromosome 3p24. Nucleic Acids Research, 20, 5587-5592.
26. Jensen, P.B., Vindelov, L., Roed, H., Demant, E.J.F., Sehested, M., Skovsgaard, T. & Hansen, H.H. (1989) In vitro evaluation of the potential of aclarubicin in the treatment of small cell carcinoma of the lung (SCCL). British Journal of Cancer, 60, 838-844.
27. Jensen, P.B., Jensen, P.S., Demant, E.J.F., Friche, E., Sørensen, B.S., Sehested, M., Wassermann, K., Vindelov, L., Westergaard, O. & Hansen, H.H. (1991) Antagonistic effects of aclarubicin on daunorubicin-induced cytotoxicity in human small cell lung cancer cells: relationship to DNA integrity and topoisomerase II. Cancer Research, 51, 5093-5099.
28. Kelleher, C., Miyauchi, J., Wong, G., Clark, S., Minden, M.D. & McCulloch, E.A. (1987) Synergism between recombinant growth factors, GM-CSF and G-CSF acting on the blast cells of acute myeloblastic leukemia. Blood, 69, 1498-1503.
29. Kristensen, J.S. & Hokland, P. (1991) Monoclonal antibodies in myeloid diseases: prognostic use in acute myeloid leukemia. Leukemia Research, 15, 693-700.
30. Lotem, J. & Sachs, L. (1992) Hematopoietic cytokines inhibit apoptosis induced by transforming growth factor β1 and cancer chemotherapy compounds in myeloid leukemia cells. Blood, 80, 1750-1757.
31. Löwenberg, B. & Touw, I.P. (1995) Hematopoietic growth factors and their receptors in acute leukemia. Blood, 81, 281-292.
32. Löwenberg, B., van Putten, W.L.J., Touw, I.P., Delwel, R. & Santini, V. (1993) Autonomous proliferation of leukemic cells in vitro as a determinant of prognosis in adult acute myeloid leukemia. New England Journal of Medicine, 328, 614-619.
33. Madsen, P.S., Hokland, P., Clausen, N., Ellegaard, J. & Hokland, M. (1995) Differential expression levels of the heat shock protein 27 isoforms in pediatric normal, nonleukemic and common acute lymphoblastic leukemia B-cell precursors. Blood, 85, 510-521.
34. Marie, J.P., Zittoun, R. & Sikic, B.I. (1991) Multidrug resistance (mdr1) gene expression in adult acute leukemias: correlation with treatment outcome and in vitro drug sensitivity. Blood, 78, 586-592.
35. Masuda, H., Ozols, R.F., Lai, G-M., Fojo, A., Rothenberg, M. & Hamilton, T.C. (1988) Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum(II) in human ovarian cancer cell lines. Cancer Research, 48, 5713-5716.
36. McGahon, A., Bissonnette, R., Schmitt, M., Cotter, K.M., Green, D.R. & Cotter, T.G. (1994) BCR-ABL maintains resistance of chronic leukemia cells to apoptotic cell death. Blood, 83, 1179-1187.
37. Mertelsmann, R., Thaler, H.T., To, L., Gee, T.S., McKenzie, S., Schauer, P., Friedman, A., Arlin, Z., Cirrincione, C. & Clarkson, B. (1980) Morphological classification, response to therapy, and survival in 265 adult patients with acute non-lymphoblastic leukemia. Blood, 56, 773-781.
38. Miyashita, T. & Reed, J.C. (1993) Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood, 81, 151-157.
39. Mosmann, T. (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. Journal of Immunological Methods, 65, 55-63.
40. Nørgaard, J.M., Langkjer, S.T., Ellegaard, J., Palshof, T., Clausen, N. & Hokland, P. (1993) Synergistic and antagonistic effects of myeloid growth factors on in vitro cellular killing by cytotoxic drugs. Leukemia Research, 17, 689-694.
41. Oki, T., Takeuchi, T., Oka, S. & Umezawa, H. (1981) New anthracycline antibiotic aclacinomycin A: experimental studies and correlations with clinical trials. Recent Results in Cancer Research, 76, 21-40.
42. Pedersen-Bjergaard, J., Brincker, H., Ellegaard, J., Drivsholm, A., Freund, L., Jensen, K.B., Jensen, M.K. & Nissen, N.I. (1984) Aclarubicin in the treatment of acute nonlymphocytic leukemia refractory to treatment with daunomycin and cytarabine: a phase II trial. Cancer Treatment Reports, 68, 1233-1237.
43. Pedersen, B. & Kerndrup, G. (1986) Specific minor chromosome deletions consistently occurring in myelodysplastic syndromes. Cancer Genetics and Cytogenetics, 23, 61-75.
44. Pedersen-Bjergaard, J., Philip, P., Mortensen, B.T., Ersbøll, J., Jensen, G., Panduro, J. & Thomsen, M. (1981) Acute nonlymphocytic leukemia, preleukemia, and acute myeloproliferative syndrome secondary to treatment of other malignant diseases: clinical and cytogenetic characteristics and results of in vitro culture of bone marrow and HLA typing. Blood, 57, 712-723.
45. Pieters, R., Huismans, D.R., Loonen, A.H., Hählen, K., van der Doesvan den Berg, A., van Vering, E.R. & Veerman, A.J.P. (1991) Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia. Lancet, 338, 399-403.
46. Preisler, H.D. (1980) Prediction of response to chemotherapy in acute myelocytic leukemia. Blood, 56, 361-367.
47. Rees, J.K.H., Gray, R.G., Swirsky, D. & Hayhoe, F.G.J. (1986) Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial. Lancet, ii, 1236-1241.
48. Rogers, S.Y., Bradbury, D., Kozlowski, R. & Russell, N.H. (1994) Evidence for internal autocrine regulation of growth in acute myeloblastic leukemia cells. Experimental Hematology, 22, 593-598.
49. Sargent, J.M. & Taylor, C.G. (1989) Appraisal of the MTT-assay as a rapid test of chemosensitivity in acute myeloid leukaemia. British Journal of Cancer, 60, 206-210.
50. Schiffer, C.A., Lee, E.J., Tomiyasu, T., Wiernik, P.H. & Testa, J.R. (1989) Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia. Blood, 73, 263-270.
51. Smith, K., Houlbrook, S., Greenall, M., Carmichael, J. & Harris, A.L., (1993) Topoisomerase IIα co-amplification with erbB2 in human primary breast cancer and breast cancer cell lines: relationship to m-AMSA and mitoxantrone sensitivity. Oncogene, 8, 933-938.
52. Swirsky, D.M., de Bastos, M., Parish, S.E., Rees, J.K.H. & Hayhoe, F.G.J. (1986) Features affecting outcome during remission induction of acute myeloid leukaemia in 619 adult patients. British Journal of Haematology, 64, 435-453.
53. Tafuri, A. & Andreeff, M. (1990) Kinetic rationale for cytokine-induced recruitment of myeloblastic leukemia followed by cycle-specific chemotherapy. Leukemia, 4, 826-834.
54. Tafuri, A., Lemoli, R.M., Chen, R., Gulati, S.C. Clarkson, B.D. & Andreeff, M. (1994) Combination of hematopoietic growth factors containing IL-3 induce acute myeloid cell sensitization to cycle specific and cycle non-specific drugs. Leukemia, 8, 749-757.
55. te Boekhorst, P.A.W., Löwenberg, B., van Kapel, J., Nooter, K. & Sonneveld, P. (1995) Multidrug resistant cells with high proliferative capacity determine response to therapy in acute myeloid leukemia. Leukemia, 9, 1025-1031.
56. Tewey, K.M., Rowe, T.C., Yang, L., Halligan, B.D. & Liu, L.F. (1984) Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science, 226, 466-468.
57. Trent, J.M. & Witkowski, C.M. (1987) Clarification of the chromosomal assignment of the human P-glycoprotein/MDR-1 gene: possible coincidence with the cystic fibrosis and c-met oncogene. Cancer Genetics and Cytogenetics, 26, 187-189.
58. Vidriales, M.B., Orfao, A., López-Berges, M.C., González, M., López-Macedo, A., Ciudad, J., López, A., García, M.A., Hernández, J.H., Borrego, D. & San Miguel, J.F. (1995) Prognostic value of S-phase cells in AML patients. British Journal of Haematology, 89, 342-348.
59. Wattel, E., Preudhomme, C., Hecquet, B., Vanrumbeke, M., Quesnel, B., Dervite, I., Morel, P. & Fenaux, P. (1994) p53 mutations are associated with resistance to chemotherapy and short survival in hematological malignancies. Blood, 84, 3148-3157.
60. Williams, G.T., Smith, C.A., Spooncer, E., Dexter, T.M. & Taylor, D.R. (1990) Haemopoietic colony stimulating factors promote cell survival by suppressing apoptosis. Nature, 343, 76-79.
61. Yates, J., Glidewell, O., Wiernik, P., Robert Cooper, M., Steinberg, D., Dosik, H., Levy, R., Hoagland, C., Henry, P., Gottlieb, A., Cornell, C., Berenberg, J., Hutchison, J.L., Raich, P., Nissen, N., Ellison, R.R., Frelick, R., Watson James, G., Falkson, G., Silver, R.T., Haurani, F., Green, M., Henderson, E., Leone, L. & Holland J.F. (1982) Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood, 60, 454-462.
62. Yonish-Rouach, E., Resnitzky, D., Lotem, J., Sachs, L., Kimchi, A. & Oren, M. (1991) Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature, 352, 345-347.
63. Young, D.C. & Griffin, J.D. (1986) Autocrine secretion of GM-CSF in acute myeloblastic leukemia. Blood, 68, 1178-1181.
64. Yunis, J.J., Brunning, R.D., Howe, R.B. & Lobell, M. (1984) High resolution chromosomes as an independent prognostic indicator in adult acute nonlymphocytic leukemia. New England Journal of Medicine, 311, 812-818.